PPARG and Parkinson disease: Pisanu et al. (2014) showed that PPAR-γ agonist rosiglitazone could switch microglia to M2 and had a helpful effect in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-intoxicated mouse model of PD. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one, EDA), an ROS scavenger, could mitigate motor dysfunction, inhibit LPS-induced microglial activation, remit declines of dopaminergic neurons in PD rats, possibly by inhibiting NLPR3 inflammasome activation and regulating microglia M1/M2 polarization (Li et al., 2021).